
About Tempus
Tempus is a publicly listed company based in Chicago (United States) founded in 2015 by Eric Lefkofsky. AI-based precision medicine solutions for oncology are provided. It operates on a AI-as-a-Service, Data-as-a-Service, and Professional Services model in Healthcare and Technology sectors. Tempus has raised $1.05 billion across 9 funding rounds from investors including Google, T. Rowe Price and Franklin Templeton. The company has 3,157 employees. Tempus has completed 5 acquisitions, including Deep 6 AI, Mpirik and Highline SCIENCES. Tempus was last valued at $6.1 billion in June 2024. Its chief executive, as recorded, is Eric Lefkofsky. Its website tempus.com draws about 151 thousand monthly visits. Tempus offers products and services including Tempus One, Tempus Lens, Tempus xM, and Tempus Pixel. Its focus areas include Precision Medicine, AI-enabled Diagnostics, Artificial Intelligence and Healthcare AI. Its competitors include Personalis, CancerIQ and Perthera; 3 of its 3 listed competitors have raised funding.
Company details
Tempus is engaged in developing AI-enabled precision medicine solutions for healthcare providers, life sciences, and patients. The company operates in sectors such as oncology, neurology, psychiatry, cardiology, and radiology. Solutions offered include genomic profiling, clinical trial matching, real-world data analysis, and diagnostic imaging. Through extensive research and partnerships, Tempus is committed to accelerating personalized patient care and transforming drug development for pharmaceutical companies. Its technology integrates with electronic health records to enhance workflow and close care gaps.
- Headquarters Chicago, United States
- Employees 3,157
- Founders Eric Lefkofsky
- Stage Public
- SectorsHealthcareTechnology
- Website category Health · Health Conditions and Concerns
- Emailβ’β’β’β’β’β’β’β’
- Phoneβ’β’β’β’ β’β’β’β’
- Website tempus.com
- Social LinkedIn X Facebook Instagram YouTube
- Legal Name Tempus Ai, Inc.
- Annual Revenue$1.27 B (USD)83.41as on Dec 31, 2025
- Net Profit-$245.03 M (USD)65.28as on Dec 31, 2025
- EBITDA-$136.31 M (USD)79.07as on Dec 31, 2025
- Total Equity Funding$1.05B (USD)
in 9 rounds
- Latest Funding Round$460M (USD), Post-IPO
Jul 2026
- InvestorsGoogle
& 11 more
- Employee Count3,157
- Investments & AcquisitionsDeep 6 AI
& 4 more
Products & Services of Tempus
Tempus offers a comprehensive portfolio of products and services, including Tempus One, Tempus Lens, Tempus xM, and Tempus Pixel.
AI assistant for healthcare providers and researchers.
Platform for accessing multimodal real-world data analysis.
Assay for monitoring immunotherapy response in cancers.
Imaging solutions for therapy response evaluation purposes.
Apps and channels of Tempus
its YouTube channel Tempus AI has 2.84K subscribers and 30 videos.
Videos from Tempus
The most watched videos on Tempus's YouTube channel, Tempus AI (2.84K subscribers). Click a video to play it here.
More on Tempus AI.
Funding Insights of Tempus
Tempus has successfully raised a total of $1.05B across 9 strategic funding rounds. The most recent funding activity was a Post-IPO round of $460 million completed in July 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1.05B
- Total Rounds 9
- Last Round Post-IPO β $460M
- First Round $70M
(Sep 2017)
- Investors Count 12
All 9 funding rounds of Tempus with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2026 | $460M | Post-IPO | β | β | β |
| Oct 2022 | Series G | β | β | β | |
| Oct 2022 | Debt – Conventional | β | β | β | |
| Dec 2020 | $200M | Series G | $8.1B | ||
| Mar 2020 | $100M | Series G | β | Baillie Gifford, Franklin Templeton Investments | β |
| May 2019 | $200M | Series F | β | Franklin Templeton Investments | |
| Aug 2018 | $110M | Series E | $2B | T. Rowe Price, Baillie Gifford | |
| Mar 2018 | $80M | Series D | β | New Enterprise Associates, Revolution | β |
| Sep 2017 | $70M | Series C | β | New Enterprise Associates, Revolution | β |
| Date | Valuation | Stage |
|---|---|---|
| Dec 2020 | $8.1B | β’β’β’β’β’β’β’β’ |
| Aug 2018 | $2B | β’β’β’β’β’β’β’β’ |
Full valuation and stage history of Tempus
Every valuation point, the growth-stage changes (minicorn, soonicorn, unicorn) and the dates behind them require an active premium plan.
- All valuation points
- Stage changes
- Dates
- Exports
Verified entity values are shown only after access is granted.
Last known valuation $6.1B (Jun 2024). 12 investors in total: 12 institutional.
Investors in Tempus
Tempus has secured backing from 12 investors, including institutional and venture fund investors. Prominent investors backing the company include Google, T. Rowe Price and Franklin Templeton.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity and venture capital fund focused on the healthcare sector | novoholdings.dk | Hellerup, Denmark | ||
Venture capital investments are offered to startups by NEA. | nea.com | Menlo Park, United States | ||
Revolution is recognized as a D.C.-based investment firm. | revolution.com | Washington, Dc, United States | ||
Tech focused seed & early stage VC firm investing primarily in the US | lightbank.com | Chicago, United States | ||
Venture capital investments are directed toward blockchain startups by Lemniscap. | lemniscap.com | George Town, Cayman Islands | ||
Early-stage venture capital arm of SoftBank Group | sbvacorp.com | Seoul, South Korea | ||
| saints-it.com | ||||
A technology company offering products and services, including search engine, cloud computing, advertising, email, productivity software, and more | 1998 | google.com | Mountain View, United States | |
Diversified investment management services are provided by the firm. | 1908 | bailliegifford.com | Edinburgh, United Kingdom | |
Diversified investment management services are offered globally by the firm. | 1947 | franklintempleton.com | New York, United States |
Investor details for Tempus
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Tempus
604 people are tracked at Tempus (208 in leadership, 5 in board & advisors, 391 in team); the tracked headcount is 3,157.
| Name | Role | Group |
|---|---|---|
Eric Lefkofsky | Founder & CEO | Leadership |
Catherine Igartua | Vice President Of Translational Research | Leadership |
Jonathan Dry | Vice President Pharma R&d | Leadership |
Maria Mikkelson | Senior Director, Atlanta Lab Systems And Informatics | Leadership |
Shane Colley | CTO | Leadership |
Diane Flasch | Associate Director | Leadership |
Ryan Fukushima | Chief Operating Officer | Leadership |
Melissa Chester | Senior Project Director | Leadership |
Arjun Ishwar | Director Omics Solutions | Leadership |
Siqi Liu | Vice President Of Machine Learning | Leadership |
Dan S. | Associate Director - Scientific Affairs | Leadership |
Jane Patel | Director, Lab Operations | Leadership |
Jim Rogers | CFO | Leadership |
Eric Ranes | Sr. Director Of Supply Chain | Leadership |
Meghan Degele | Sr. Director, Clinical Research Partnerships | Leadership |
Kate Sasser | Chief Scientific Officer | Leadership |
Shelley MacNeil | Director Of Data Solutions | Leadership |
Christoff Coetzee | Senior Director: Process Engineering And Automation | Leadership |
Darren Wozniak | Key Account Director - Research Services And Cdx | Leadership |
Ira Klein | Vice President, Medical Affairs & Payer Relations | Leadership |
584 more people are available in the full profile.
Complete people profiles for Tempus
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Tempus
Tempus is a publicly listed company on the NASDAQ with ticker symbol TEM in USA, operating in the Technology services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date14 Jun 2024
- Listed onNASDAQ: TEM
- Listed entityTempus AI, Inc.
- Exchange sectorTechnology services
- ISINUS88023B1035
- Share price$68.22 (+0.34% on the day) · 2026-10-13
- Market capitalisation$12.31B
- EPS (diluted, trailing year)$-1.44
- Volume (last session)4,157,626
Financials of Tempus
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $1.27B | -$245.0M | -$136.3M |
| 2024 | $693.4M | -$705.8M | -$651.1M |
| 2023 | $531.8M | -$214.1M | -$163.2M |
| 2022 | $320.7M | -$289.8M | -$238.7M |
| 2021 | $257.9M | -$259.2M | -$220.1M |
Detailed financial statements for Tempus
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Tempus
Tempus has strategically engaged in corporate development activities, having acquired 5 companies. Notable acquisitions include Deep 6 AI, Mpirik and Highline SCIENCES.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
AI-enabled tools for computational pathology and cancer diagnostics are provided. | paige.ai | New York, United States | 2018 | Aug 2025 | $81.25M | |
AI enabled solutions for clinical trials | deep6.ai | Pasadena, United States | 2013 | Mar 2025 | β’β’β’β’ | |
Genetic testing is provided for clinical diagnostics and genomic services. | ambrygen.com | Aliso Viejo, United States | 1999 | Nov 2024 | $600M | |
Orthopedic care management platforms are provided for clinics and hospitals. | mpirik.com | Milwaukee, United States | 2011 | Mar 2023 | β’β’β’β’ | |
CRO focused on clinical development services for oncology drugs | highlinesciences.com | San Francisco, United States | 2018 | Feb 2022 | β’β’β’β’ |
Complete acquisition details for Tempus
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Tempus
10 dated milestones of Tempus across 11 years, from founding to its latest funding, stage changes and deals.
- Founded Tempus is founded.
- Funding First funding round of $70.0M.
- Milestone Reaches Unicorn status.
- Acquisition Acquires Highline SCIENCES.
- Acquisition Acquires Mpirik.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Ambry Genetics.
- Acquisition Acquires Deep 6 AI.
- Acquisition Acquires PAIGE.
- Funding Latest funding round, Post-IPO, of $460.0M.
Competitors of Tempus
Tempus has 3 listed competitors in our database, 3 of them funded. They include Personalis, CancerIQ and Perthera.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| personalis.com | 2011 | Menlo Park, United States | $87.3M | 310 | Genomic sequencing and diagnosis software is provided for healthcare. | |
| canceriq.com | 2013 | Chicago, United States | $23.87M | 78 | CancerIQ is focused on precision cancer prevention and care. | |
| perthera.com | 2012 | Mclean, United States | $17.02M | 13 | Molecular cancer profiling is conducted via genomics and proteomics. |
Detailed competitors of Tempus
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Tempus
The website of Tempus (tempus.com) receives about 150.9K visits a month and ranks #320,246 among all websites worldwide, #11,224 in Health Conditions and Concerns.
- Monthly visits150.9K
▲ 13.5% vs previous month
- Unique visitors66.5K
per month
- Global rank#320,246
among all websites
- Category rank#11,224
Health · Health Conditions and Concerns
- Bounce rate47%
- Pages per visit1.8
- Average visit40 sec
- DevicesDesktop 51% Β· Mobile 49%
Websites whose visitors overlap most with Tempus. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
tempusunlimited.org | tempusunlimited.org | 100% | #102,804 | β | |
| aruplab.com | 92% | 138.9K | #300,732 | View details | |
| castlebiosciences.com | 92% | 26.9K | #985,933 | View details | |
| cccnevada.com | 92% | #2,017,364 | View details | ||
| foxchase.org | 92% | 111.1K | #341,787 | View details | |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
All 25 similar websites and full traffic analytics for Tempus
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 25 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Clinical IT & Data Platforms
3 companies that operate in the same segment as Tempus (Clinical IT & Data Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Employee health benefits are facilitated via a cloud-based platform. | 2007 | Plymouth Meeting, Pennsylvania, United States | USD 228.3 M | |||
Healthcare appointments are booked online via Zocdoc's platform. | 2007 | New York, New York, United States | USD 425.97 M | USD 4.66 M | 1,365 | |
Virtual physical therapy and digital pain care solutions are provided. | 2015 | San Francisco, California, United States | USD 854.44 M | 1,746 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Tempus
Complete news archive for Tempus
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Tempus
Tempus was founded in 2015 and raised its 1st funding round 2 years after it was founded.
Tempus is headquartered in Chicago, United States. It is registered at Chicago, Illinois, United States.
Eric Lefkofsky is the CEO of Tempus, as recorded in our data. They have also founded this company.
Tempus is a funded company, having raised a total of $1.05B across 9 funding rounds to date. The company's 1st funding round was a Series C of $70M, raised on Sep 2017.
Tempus has 3,157 employees.
Annual revenue of Tempus is $1.27B as on Dec 31, 2025.
Tempus is engaged in developing AI-enabled precision medicine solutions for healthcare providers, life sciences, and patients. The company operates in sectors such as oncology, neurology, psychiatry, cardiology, and radiology. Solutions offered include genomic profiling, clinical trial matching, real-world data analysis, and diagnostic imaging. Through extensive research and partnerships, Tempus is committed to accelerating personalized patient care and transforming drug development for pharmaceutical companies. Its technology integrates with electronic health records to enhance workflow and close care gaps.
Tempus's top competitors include Personalis, CancerIQ and Perthera.
Tempus offers Tempus One, Tempus Lens, Tempus xM, and Tempus Pixel.
Yes, Tempus is publicly traded on NASDAQ under the ticker symbol TEM.
Tempus has made 5 acquisitions, including Deep 6 AI, Mpirik, and Highline SCIENCES.
Tempus has 12 investors. Key investors include Google, T. Rowe Price, Franklin Templeton, Baillie Gifford, and Novo Holdings.
